Cambridge, UK/MA, September 11 2019: Cedilla Therapeutics and o2h Discovery are pleased to announce multi FTE expansion to their synthetic chemistry collaboration with Cedilla Therapeutics, a Third Rock backed biotech company based in the Cambridge MA.

Cedilla Therapeutics is discovering and exploiting unique insights into protein stability. Cedilla’s integrated, multi-faceted approach has the potential to broaden the reach of small molecules by generating therapeutics that degrade protein targets as their primary mechanism of action.

o2h is pleased to collaborate with Cedilla, to support their aim of charting new paths to target proteins that have long been outside the reach of drug discovery and development. The avenue of research adopted by Cedilla is exciting and the team is committed to broadening the reach of small molecule therapeutics to address cancer and other diseases caused by protein dysregulation.

Sunil Shah, CEO of o2h Discovery, said “It has been a great pleasure to support Cedilla with their discovery efforts for over a year and we are delighted to extend our collaboration further by significant expansion to the current team.”

C. Eric Schwartz, Vice President of Drug Discovery, Cedilla, commented “o2h has been a very valuable and trusted partner and have shown commitment and delivery to our discovery goals by providing incomparable support. We are excited with this expansion and would like to thank chemists and biologist at o2h for their excellent support.”

About o2h Discovery

Founded in 2005, o2h Discovery has an integrated drug discovery platform operating from our state-of-the-art research centre in India and The Mill SciTech Park, Cambridge, UK. We have the in-house capability to execute hit-lead-optimization programs leading into patent and IND filing from our state-of-the-art biotechnology incubator with expertise in discovery chemistry, biology, pharmacology and the on-going project management of pre-clinical development.

o2h Discovery has developed and launched its proprietary application AI Chemistry in the CloudTM(AI-CITC) which is the world’s first app to revolutionize the project management of external drug discovery programs. The app enables communication between various scientific stakeholders essential to successful project advancement – leading to faster decision making.

The DNA of o2h is centered around the nurturing of its people, values and culture, it reflects in the way we work with each other, as well as our collaborators and partners.

For more information, please visit www.o2h.com

About Cedilla Therapeutics

Cedilla Therapeutics is discovering and exploiting unique insights into protein stability. Cedilla’s integrated, multi-faceted approach has the potential to broaden the reach of small molecules by generating therapeutics that degrade protein targets as their primary mechanism of action. The approach harnesses intrinsic degradation pathways that are upstream of ubiquitination. Cedilla is focused on destabilizing oncoprotein targets using a product engine that is also applicable to targets outside of oncology. Cedilla was launched in 2018 by Third Rock Ventures and is based in Cambridge, Mass.

For more information, please visit www.cedillatx.com or follow us on LinkedIn.